Aman, M. G. (1996). Stimulant drugs in the developmental disabilities revisited. Journal of Developmental and Physical Disabilities, 8, 347-365.
Google Scholar
Aman, M. G., Arnold, L. E., & Armstrong, S. C. (1999). Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 279-289.
Google Scholar
Aman, M. G., & Langworthy, K. S. (2000). Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. Journal of Autism and Developmental Disorders, 30, 451-459.
Google Scholar
Aman, M. G., & Madrid, A. (1999). Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 253-263.
Google Scholar
Aman, M. G., Sarphare, G., & Burrow, W. (1995). Psychoactive drugs in group homes: Prevalence and relation to demographic/ psychiatric variables. American Journal on Mental Retardation, 99, 500-509.
Google Scholar
Aman, M. G., Van Bourgondien, M. E., Wolford, P. C., & Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1672-1681.
Google Scholar
Bates, W. J., Smeltzer, D. J., & Arnoczky, S. M. (1986). Appropriate and inappropriate use of psychotherapeutic medications for institutionalized mentally retarded persons. American Journal of Mental Deficiency, 90, 363-370.
Google Scholar
Baumeister, A. A., Sevin, J. A., & King, B. H. (1998). Neuroleptic medications. In S. Reiss & M. G. Aman (Eds.), Psychotropic medication and developmental disabilities: The International Consensus handbook (pp. 133-150). Columbus, OH: The Ohio State University Nisonger Center.
Google Scholar
Findling, R. L., Maxwell, K., Scotese-Wojitila, L., Huang, J., Yamashita, T., & Wiznitzer, M. (1997). High-dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in a double-blind, placebo-controlled study. Journal of Autism and Developmental Disorders, 27, 467-478.
Google Scholar
Fraser, W. I., Ruedrich, S., Kerr, M., & Levitas, A. (1998). Beta-adrenergic blockers. In S. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The international consensus handbook (pp. 271-289). Columbus, OH: The Ohio State University Nisonger Center.
Google Scholar
Hagerman, R., Bregman, J. D., & Tirosh, E. (1998). Clonidine. In S. R. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The international consensus handbook (pp. 259-270). Columbus, OH: The Ohio State University Nisonger Center.
Google Scholar
Heberlein, T. A., & Baumgarner, R. (1978). Factors affecting response rates to mailed questionnaire: A quantitative analysis of the published literature. American Sociological Review, 43, 447-462.
Google Scholar
Institute of Medicine (Food and Nutrition Board). (1998). National Academy of Sciences. Washington, DC: National Academy Press.
Google Scholar
Kerlinger, F. N., & Lee, H. B. (2000). Survey Research. In F. N. Kerlinger & H. B. Lee (Eds.), Foundation of behavioral research, 4th ed., (pp. 599-619). Orlando, FL: Harcourt, Inc.
Google Scholar
Martin, A., Scahill, L., Klin, A., & Volkmar, F. (1999). Higher-functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 923-931.
Google Scholar
Research Units on Pediatric Psychopharmacology Autism Network (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314-321.
Google Scholar
Rimland, B. (1988). Controversies in the treatment of autistic children: Vitamin and drug therapy. Journal of Child Neurology, 3, S68-S72.
Google Scholar
Rinck, C. (1998). Epidemiology and psychoactive medication. In S. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The international consensus handbook (pp. 31-44). Columbus, OH: The Ohio State University Nisonger Center.
Google Scholar
Rush, A. J., & Frances, A. (Eds.). (2000). Expert guideline series: Treatment of psychiatric and behavioral problems in mental retardation [Special issue]. American Journal on Mental Retardation, 105(3).
Schaumburg, H., Kaplan, J., Windebank, A., Vick, N., Rasmus, S., Pleasure, D., & Brown, M. J. (1983). Sensory neuropathy from pyridoxine abuse: A new megavitamin syndrome. New England Journal of Medicine, 309, 445-448.
Google Scholar
Schlesselman, J. J. (1982). Case control studies. Design, conduct, analysis. New York: Oxford University Press.
Google Scholar
Singh, N. N., Ellis, C. R., Mulick, J. A., & Poling, A. (1998). Vitamin, mineral, and dietary treatments for individuals with developmental disabilities. In S. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The International Consensus handbook (pp. 311-320), Columbus, OH: The Ohio State University Nisonger Center.
Google Scholar
Singh, N. N., Ellis, C. R., & Wechsler, H. A. (1998). Psychophar-macoepidemiology in mental retardation. Journal of Child and Adolescent Psychopharmacology, 7, 255-266.
Google Scholar
Walter, S. D., Feinstein, A. R., Wells, C. K. (1987). Coding ordinal independent variables in multiple regression analyses. American Journal of Epidemiology, 125, 319-323.
Google Scholar